The Alliance for Human Research Protection is proud to have played a role in helping to open a public debate about Merck's flagrant commercial push to influence public officials into mandating its human papilloma virus (HPV) vaccine, Gardasil, for girls aged 11 to 26.
"I am so bothered by the speed by which adults are ready to put chemicals into little girls bodies without a full understanding of what harm those chemicals could cause in the short and long term. Continue reading →
Only if one assumes that the FDA sees the drug industry as its client can some sense be made of December 13th meeting of the FDA’s Psychopharmacologic Drugs Advisory Committee in Silver Springs, Maryland.
The New York Times is calling for congressional hearings after the revelations that Eli LillyDocumented evidence reveal that Eli Lilly glossed over the debilitating hazards of Zyprexa–and aggressively marketed it to primary care physicians. Continue reading →
Expert Scientists, Psychiatrists, a Primary Care Physician, a Leading Attorney, will shed light on FDA’s Review of selected data Re: Antidepressants and Adult Suicidality One day prior to FDA’s Advisory Committee Hearing, December 13.
Off-label prescribing of drugs for unapproved uses puts consumers at high risk of harm–but it is the single most lucrative marketing strategy. Continue reading →
"The drugs most commonly used to soothe agitation and aggression in people with Alzheimer’s disease are no more effective than placebos for most patients, and put them at risk of serious side effects, including confusion, sleepiness and Parkinson’s disease-like symptoms, researchers are reporting
today." Continue reading →
A Special Article By Curt D. Furberg, MD, PhD; Arthur A. Levin, MPH; Peter A. Gross, MD; Robyn S. Shapiro, JD; Brian L. Strom, MD, MPH
Tomorrow Hearing FDA’s Emergency Research Rule–CNN News at 8:00 P.M will inform the public about how the FDA Rule impacts on American citizens who can be put at increased risk to test an experimental treatment without their knowledge or consent.
Two actions by the FDA last week demonstrate where the agency’s priority lies—and that priority is NOT to protect public safety, NOT to protect children’s safety. FDA’s priority—as demonstrated by its actions—is approval of new drugs or approval for expanded even dubious uses of patented drugs.
A report by the Institute of Medicine is sharply critical of FDA’s drug safety monitoring system: "The report’s conclusions are striking and often damning – particularly when discussing the agency’s Center for Drug Evaluation and Research, known as C.D.E.R."
Evidence of an association between violence and widely prescribed antidepressant drugs is the focus of this Infomail. Continue reading →